Back to search results

Phase II Study of CD5 CAR Engineered IL15-transduced Cord Blood-derived NK Cells for Aggressive T Cell Cancers

This study is testing a new treatment for aggressive T-cell blood cancers. It uses special immune cells called iC9/CD5CAR/IL-15 NK cells, along with chemotherapy drugs like Rituximab, Fludarabine, and Cyclophosphamide. The goal is to see how safe and effective this treatment is in patients aged 18 to 80 who have T-cell cancers that express at least 30% CD5 on their tumor cells. The main things researchers are looking for are any side effects and how well the treatment prevents the cancer from coming back after one year. This study plans to enroll about 70 participants.

Study design
This is an interventional study with an unclear phase, planning to enroll 70 participants. It is testing a new cell therapy alongside chemotherapy.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Safety and side effects will be measured through study completion, which is an average of one year.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07137481

Phase II Study of CD5 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Aggressive T Cell Hematological Malignancies

Not Yet Recruiting
PHASE2Ages 18–80InterventionalTreatment
M.D. Anderson Cancer Center
~70 participants
Updated 2026-08-20 on ClinicalTrials.gov
What's tested:C9/CD5CAR/IL-15 NK cellsRituximabFludarabineCyclophosphamide

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Safety and Adverse Events (AEs)
Measured over Through study completion; an average of 1 year

Conditions

Hematological Malignancies

Explore related trials

Anaplastic Large Cell LymphomaFollicular Helper T-Cell Lymphoma, Angioimmunoblastic-TypeHematologic NeoplasmHepatosplenic Gamma/Delta Non-Hodgkin LymphomaMature T-Cell and NK-Cell Non-Hodgkin LymphomaPre T-ALLT-Cell Non-Hodgkin LymphomaT-Cell Prolymphocytic LeukemiaT Lymphoblastic LymphomaCD5 Gene

Where it's being run

1 sites across 1 states
Texas1

Study leadership

  • Chitra Hosing, MD · PRINCIPAL_INVESTIGATOR · M.D. Anderson Cancer Center

Who to contact

Chitra Hosing, MD
[email protected]
(713) 745-3219
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Postmenopausal (no menses in greater than or equal to 12 consecutive months).
History of hysterectomy or bilateral salpingo-oophorectomy.
Ovarian failure (Follicle Stimulating Hormone and Estradiol in menopausal range, who have received Whole Pelvic Radiation Therapy).
History of bilateral tubal ligation or another surgical sterilization procedure.

What this trial measures

  • Safety and Adverse Events (AEs)Through study completion; an average of 1 year

    Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0